Anika Therapeutics (ANIK) Stock Overview
A joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ANIK from our risk checks.
ANIK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Anika Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.10 |
| 52 Week High | US$16.24 |
| 52 Week Low | US$7.87 |
| Beta | 0.23 |
| 1 Month Change | 1.96% |
| 3 Month Change | 5.74% |
| 1 Year Change | 40.60% |
| 3 Year Change | -41.88% |
| 5 Year Change | -65.81% |
| Change since IPO | 331.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANIK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.7% | 5.1% | -2.7% |
| 1Y | 40.6% | 36.7% | 18.6% |
Return vs Industry: ANIK exceeded the US Biotechs industry which returned 36.7% over the past year.
Return vs Market: ANIK exceeded the US Market which returned 18.6% over the past year.
Price Volatility
| ANIK volatility | |
|---|---|
| ANIK Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANIK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANIK's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 235 | Steve Griffin | www.anika.com |
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products.
Anika Therapeutics, Inc. Fundamentals Summary
| ANIK fundamental statistics | |
|---|---|
| Market cap | US$194.53m |
| Earnings (TTM) | -US$11.08m |
| Revenue (TTM) | US$116.26m |
Is ANIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANIK income statement (TTM) | |
|---|---|
| Revenue | US$116.26m |
| Cost of Revenue | US$48.14m |
| Gross Profit | US$68.12m |
| Other Expenses | US$79.20m |
| Earnings | -US$11.08m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 58.59% |
| Net Profit Margin | -9.53% |
| Debt/Equity Ratio | 0% |
How did ANIK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 22:44 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anika Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Landy | Northland Capital Markets |